PDL BioPharma — Jefferies 2018 Healthcare Conference
28 slides from PDL BioPharma's conference presentation, Jun 5, 2018

Slide 1: Jefferies 2018 Healthcare Conference
PDL Jefferies 2018 Healthcare Conference June 5, 2018 PDL BioPharma, Inc. Nasdaq: PDLI

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements including PDL's expectations with respect to its future royalty revenues, expenses, net income and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actual

Slide 3: PDL's Evolving Strategy
PDL’s Evolving Strategy Maximize shareholder value through the acquisition, nurturing and monetization of a portfolio of healthcare companies. Strategic focus on developing and capturing the value of a growing portfolio of operating companies: + Noden Pharma DAC, a specialty pharma company domiciled

Slide 4: Investment Highlights
Investment Highlights Noden Pharma has built an efficient, global commercial structure for the commercialization of cardiovascular and primary care products: - Generating profitable cash flows with Tekturna® / Rasilez®, leveraging recently stabilized U.S. Rx trends and well-targeted international ma

Slide 5: Business Development and M&A Strategy
Business Development and M&A Strategy Whatwe are looking for: * Commercial-stage products and/or companies whose performance may be improved through access to PDL’s capital and expertise. + Late-stage assets with positive Phase 3 data awaiting regulatory approval. + Biopharma products or companies t

Slide 6: Leadership with Proven Track Record
Leadership with Proven Track Record Executive Management Capabilities & Accomplishments John McLaughlin, CEO * $1 billion in completed transactions Dominique Monnet, President Muitiplesuccesstulll0s * Commercial productlaunches and Geter Cateig CFO. growth in the US and internationally Shriststoners

Slide 7: Noden Pharma
PDL NODEN y PHARMA

Slide 8: The Noden Transaction
The Noden Transaction * Noden Pharma _and Tekturna ®/Rasilez® were PDL’s first operational acquisitions under its new business strategy. * Total Tekturna®/Rasilez® potential purchase price from Novartis is up to $294 million. — $110 million paid at closing in July 2016 and $89 million paid at first

Slide 9: Current Noden Products
Current Noden Products Tekturna® (U.S.), Rasilez® (ex-U.S.) — contain aliskiren, the first and only approved direct renin inhibitor for the management of hypertension. - Not for use with ACE inhibitors or ARBs in patients with diabetes or renal impairment, pregnant women and pediatric patients below

Slide 10: The Tekturna Opportunity
The Tekturna® Opportunity Hypertension is a chronic condition with serious long-term health implications, affecting nearly 50% of all adults in the U.S.1 Angiotensin Converting Enzyme Inhibitors (ACEls) and Angiotensin Il Receptor Blockers (ARBs) are typically first- and second-line therapies. Tektu

Slide 11: Executing on the Commercial Side...
"1 Executing on the Commercial Side... ACE/ ARB Intolerant: SWITCH CCB Notat Goal: ADD Your Patients on Hypertension Monotherapy May Have Uncontroled BP” % Aad as many a5 50% i] D ists Estimated 3.3 million patients Estimated 6 million patients

Slide 12: ...and on the Access Side
12 ...and on the Access Side Source of Tekturna® Business Tekturna® Plan Coverage 42% 53% Commercial Medicare D Jan-18 m= Preferred = Preferred (PA/ST) = Commercial m Medicare All Other = Covered = Covered (PAST) = Cash = All Medicaid = Not Covered Source: IQVIA PlanTrak & Managed Markets Insight &

Slide 13: Stabilizing Tekturna U.S. Prescriptions
Stabilizing Tekturna® U.S. Prescriptions Tekturna Prescription Data - All Strengths (U.S.) Noden resumes promotion with 40 reps Noden field force increased to 60 reps

Slide 14: Maximizing Rasilez Profitability Ex-U.S.
Maximizing Rasilez® Profitability Ex-U.S. Reviewed each ex-U.S. market and determined to: — Make no investments in direct promotions. — De-register the products in unprofitable markets. - Identify and pursue growth geographies. Actions: - EU: Nov. 2017 assumed commercialization in the EU and Switzer

Slide 15: Tekturna/Rasilez Intellectual Property
Tekturna®/Rasilez® Intellectual Property * United States - Composition-of-matter protection to 2018 for Tekturna®; listed in the Orange Book; — Plus 6-month extension from successful completion of pediatric testing requirements. ~ Composition-of-matter protection until 2022 for Tekturna® HCT. ~ Form

Slide 16: LENSAR: Cataract Laser with Augmented Reality
PDL CATARACT LASER WITH AUGMENTED REALTY

Slide 17: LENSAR
7 | LENSAR Converted debt to equity in May 2017. - $119 million in NOLs available. - To consider an exit when shareholder value is maximized. Leading global developer and manufacturer of femtosecond cataract lasers (FLS) for cataract surgery. Cataract surgery is the No. 1 surgical procedure globally

Slide 18: LENSAR Highlights
48 LENSAR Highlights Leading Technology Platform Positioned for Growth >26 million cataract surgeries estimated in 2017. Integrating preop diagnostics is driving growth by delivering better outcomes. Existing treatments are sub-optimal for astigmatism (100% of cataract patients). Widely recognized a

Slide 19: Royalty and Debt Portfolio
PDL Royalty and Debt Portfolio

Slide 20: Concluded Royalty and Debt Investments
Concluded Royalty and Debt Investments Generated 15.9% IRR Royalty Transaction ‘Senior Secured Financing Wellstat Diagnostics, LUC we $44,000,000 November2012 Royalty Acquisition 3% Depomed 240,500,000 October 2013, ‘Senior Secured Financing A | LENSAR $60,000,000 October 2013, ‘Senior Secured Finan

Slide 21: Cash Flow Funds the New Business Strategy
Cash Flow Funds the New Business Strategy: $19.3 million in Q1-2018 indefinite i 6/2018 Bi \ Ome fi 5/2026 p) $240.5M $325.4M > janssen (9/2023 Br | Qi! a, 12/2026 ll J = Payoff $100.0M — $120.0M? “ARIAD ice . 4/2022 $65.6M $9.2M cave: S SANOFI GENZYME ZALVISO” 1/2032 $65.0M $0.2M Sura SE aceD ELEY

Slide 22: Financials
PDL Financials

Slide 23: First Quarter 2018 Income Statement
First Quarter 2018 Income Statement Three Months Ended Key Points March 31, (in thousands, except per share amounts) 2018 2017 Royalties from Queen et al. patents S 2,783. _§ 14,156 *Queen et al. patent Royalty rights - change in fair value 11,091 13.146 ‘ Interest revenue 749 5,457 royalties expect

Slide 24: Strong Balance Sheet
Strong Balance Sheet ($ in millions) Cash, cash equivalents and short-term investments $405 Total Assets $1,100 Debt: 2.75% Convertible Debt — due 12/2021 ($3.81 conversion price)? $150 1) PDLentered into a capped call transaction to offset potential dilution subject to a cap of $4.88. PDL

Slide 25: A History of Value Creation
A History of Value Creation Book value per share reached $5.60 as of Mar PDL's Book Value Per Share” a oO SPRPENNNNUWUW ERENT D REASRSASRSASRSASRSasRSas 2 8 3 & & 2°23 a2 2 8 8 8 5 5 & & 8 @ 8 & §€ ¢@ & § @ & € @ @ § € &@ B&B §& § & ¢ 8 8 2 3 &§ 328 86 3 #8 & 8 (1) Does not include asset value of ro

Slide 26: High-Quality Asset Value
High-Quality Asset Value Assets 1200 Balance 3/31/2018 1000 Selected Component $ millions Per Share 800 Royalty Rights $ 3417 $ 227 Noden & LensarBook Value $ 213.2 $ 142 600 Notes Receivable $70.7 $0.47 Total Investments $ 625.6 $ 4.16 400 EE Cosh $405.1 $2.69 200 Debt $ (150.0) $ (1.00) Net Cash $

Slide 27: Share Repurchase Program
Share Repurchase Program « While our focus is on the strategic acquisition of biopharma assets, given the significant discount of PDL’s stock price to its book value, we have implemented share repurchase programs to return value to shareholders. ¢ Current Program — $25 Million - In September 2017 PD

Slide 28: Why Invest in PDLI?
Why Invest in PDLI? Upside from the new business model
Source: SEC EDGAR · 8-K filed Jun 5, 2018
More decks from PDL BioPharma Inc
Q3 2020 Earnings Presentation13 slides · Nov 13, 2020
Investor Presentation (September 2020)32 slides · Sep 10, 2020
Q2 2020 Earnings Presentation17 slides · Aug 6, 2020
Investor Presentation (July 2020)30 slides · Jul 17, 2020
Q1 2020 Earnings Presentation15 slides · May 7, 2020
Q4 2019 Earnings Presentation16 slides · Mar 11, 2020